Evidence map›Paper›PMID 40132017›Full record

ArticleACS chemical neuroscience2025

Preclinical Profile of CM699 as a Medication Candidate for Stimulant Use Disorder.

Takato Hiranita, Weimin C Hong, Abhisheak Sharma, Jessica P Lopez, Christophe Mesangeau, Daniel A Whittaker, Walid Alsharif, Theresa A Kopajtic, Seshulatha Jamalapuram, Bonnie A Avery and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Takato HiranitaDepartment of Pharmacology, Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229, United States.ORCID 0009-0000-2494-2754
Weimin C HongDepartment of Pharmaceutical Sciences, Butler University, Indianapolis, Indiana 46208, United States.
Abhisheak SharmaDepartment of Pharmaceutics, University of Florida, Gainesville, Florida 32610, United States.ORCID 0000-0003-0553-4039
Jessica P LopezPsychobiology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, United States.
Christophe MesangeauDepartment Biomolecular Sciences, University of Mississippi, University, Mississippi 38677, United States.
Daniel A WhittakerDepartment of Pharmaceutical Sciences, Butler University, Indianapolis, Indiana 46208, United States.
Walid AlsharifDepartment Biomolecular Sciences, University of Mississippi, University, Mississippi 38677, United States.ORCID 0000-0001-7513-487X
Theresa A KopajticPsychobiology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, United States.
Seshulatha JamalapuramDepartment of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University Mississippi 38677, United States.
Bonnie A AveryDepartment of Pharmaceutics, University of Florida, Gainesville, Florida 32610, United States.
Gianluigi TandaMedication Development Program, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, United States.
Christopher R McCurdyDepartment of Pharmaceutics, University of Florida, Gainesville, Florida 32610, United States.ORCID 0000-0001-8695-2915
Jonathan L KatzPsychobiology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, United States.

Funding

Investigation On The Behavior And Related Neuro-Electrochemistry Of Potential Medications For The Treatment Of Substance Use Disorders.ZIADA000611 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI TANDA, GIANLUIGI · 2016 to 2025
$16.0M
Basic Dopamine Transporter Mechanisms Of CocaineZIADA000103 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI KATZ, JONATHAN L · 2009 to 2016
$4.6M
BASIC MECHANISMS OF COCAINE'S BEHAVIORAL EFFECTSZ01DA000103 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI KATZ, JONATHAN L · 1991 to 2008
$3.0M
Novel Pharmacologic Interventions for Drugs of AbuseR01DA023205 · NIDA · UNIVERSITY OF MISSISSIPPI · PI MCCURDY, CHRISTOPHER R · 2007 to 2011
$1.7M
Gabapentinoid/opioid mixtures: abuse and toxicityR01DA058018 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Takato Hiranita · 2023 to 2026
$1.7M
Intramural NIH HHS Z01 DA000103Intramural NIH HHS ZIA DA000103Intramural NIH HHS ZIA DA000611NIDA NIH HHS R01 DA023205NIDA NIH HHS R01 DA058018
6 · The paper itself

Abstract

There currently are no medications proven to be effective for the treatment of stimulant-use disorder (SUD). Sigma-receptor (σR) antagonists block many effects of stimulant drugs but not the reinforcing effects assessed with self-administration in rats. However, a recent study suggests that σR antagonism combined with a dopamine (DA) transporter (DAT) blockade selectively attenuates stimulant self-administration. A compound with potential for dual DAT/σR inhibition, CM699, was synthesized and had the necessary

Indexed as

Central Nervous System StimulantsReceptors, sigmaSubstance-Related DisordersAnimalsCocaineDopamineDopamine Plasma Membrane Transport ProteinsDopamine Uptake InhibitorsMaleNucleus AccumbensRatsRats, Sprague-DawleySelf AdministrationCentral Nervous System StimulantsCocaineDopamineDopamine Plasma Membrane Transport ProteinsDopamine Uptake InhibitorsReceptors, sigmacocainedopamine transporterself-administrationsigma1 receptorstimulant use disorder

Identifiers

PMID40132017
PMCPMC12408108

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.